ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party

Overview of attention for article published in Frontiers in immunology, December 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 33,958 followers.

#ProducciónCientífica @hospital_hvn: "ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complication…" #DifundeCiencia #HUVNdivulga #HUVNinvestiga https://t.co/ghPid9NnXd https://t.co/84vfs9c2D8🔝Q1 IF: 7

29 Dec 2023

Reply Repost Favourite

https://t.co/kavEPKmekr

12 Dec 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant comp…

11 Dec 2023

Reply Repost Favourite

New Research: ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party: Introduction Extracorporal Photophoresis (ECP) is in clinical use for steroid-refractory and… https://t.co/vH

11 Dec 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.